行情

CMRX

CMRX

Chimerix
NASDAQ

实时行情|Nasdaq Last Sale

1.480
-0.010
-0.67%
已收盘, 16:00 03/30 EDT
开盘
1.490
昨收
1.490
最高
1.550
最低
1.425
成交量
55.87万
成交额
--
52周最高
4.400
52周最低
1.190
市值
9,137.62万
市盈率(TTM)
-0.7359
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CMRX价格均价为5.00,最高价位7.00,最低价为3.000。

EPS

CMRX 新闻

更多
  • 瑞银:随着库存增加 布伦特和WTI原油价格必将跌破20美元
  • 新浪财经 · 1小时前
  • 印尼央行行长Warjiyo称东盟的央行开会讨论刺激措施
  • 新浪财经 · 1小时前
  • 特朗普普京通话推涨美油逾5% 但原油市场仍阴云笼罩
  • 21世纪经济报道 · 2小时前
  • 沪指高开低走收涨0.11% 中国制造业PMI“意外”重返扩张
  • 新浪财经 · 2小时前

所属板块

生物技术和医学研究
+4.00%
制药与医学研究
+4.75%

热门股票

代码
价格
涨跌幅

CMRX 简况

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.
展开

微牛提供Chimerix Inc(NASDAQ-CMRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CMRX股票新闻,以帮助您做出投资决策。